Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 6/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582055 | 1.00 | CACNA1B (0.47) | CACNA1BCTSKKMT2AMAPTCYP3A4 | |
| SCHEMBL7036592 | 0.92 | CTSK (0.51) | CACNA1BCTSKKMT2ACYP2C19 | |
| SCHEMBL4902191 | 0.92 | CTSK (0.51) | CACNA1BCTSKKMT2ACYP2C19 | |
| SCHEMBL5099149 | 0.91 | MMP2 (0.48) | CACNA1BCTSKKMT2A | |
| SCHEMBL5099152 | 0.91 | MMP2 (0.48) | CACNA1BCTSKKMT2A | |
| SCHEMBL7562941 | 0.91 | MMP2 (0.48) | CACNA1BCTSKKMT2A | |
| SCHEMBL5099103 | 0.88 | CTSK (0.47) | CTSK | |
| SCHEMBL5099105 | 0.88 | CTSK (0.47) | CTSK | |
| SCHEMBL5105698 | 0.86 | CACNA1B (0.46) | CACNA1BCTSK | |
| SCHEMBL5105702 | 0.86 | CACNA1B (0.46) | CACNA1BCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259856-A1 | Method for Activating Trpv4 Channel Receptors by Agonists | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259856-A1 | Method for Activating Trpv4 Channel Receptors by Agonists | TRPV4, TRPV2, TRPV3 | CACNA1B 132/4885CTSK 410/4885KMT2A 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.